{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T19:36:51Z","timestamp":1767382611311},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1093\/mutage\/gei038","type":"journal-article","created":{"date-parts":[[2005,5,31]],"date-time":"2005-05-31T22:38:24Z","timestamp":1117579104000},"page":"297-303","source":"Crossref","is-referenced-by-count":22,"title":["Organ specificity of DNA adduct formation by tamoxifen and \u03b1-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment"],"prefix":"10.1093","volume":"20","author":[{"given":"David H.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Hewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen J.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyd","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker M.","family":"Arlt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,31]]},"reference":[{"key":"key\n\t\t\t\t20171013054448_B1","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351, 1451\u20131467.","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"key\n\t\t\t\t20171013054448_B2","doi-asserted-by":"crossref","unstructured":"Cuzick,J., Powles,T., Veronesi,U., Forbes,J., Edwards,R., Ashley,S. and Boyle,P. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361, 296\u2013300.","DOI":"10.1016\/S0140-6736(03)12342-2"},{"key":"key\n\t\t\t\t20171013054448_B3","unstructured":"IARC (1996) Tamoxifen. In: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, No. 66, Some Pharmaceutical Drugs. International Agency for Research on Cancer, Lyon, France, pp. 253\u2013365."},{"key":"key\n\t\t\t\t20171013054448_B4","doi-asserted-by":"crossref","unstructured":"Swerdlow,A.J. and Jones,M.E. (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case\u2013control study. J. Natl Cancer Inst., 97, 375\u2013384.","DOI":"10.1093\/jnci\/dji057"},{"key":"key\n\t\t\t\t20171013054448_B5","unstructured":"Greaves,P., Goonetilleke,R., Nunn,G., Topham,J. and Orton,T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919\u20133924."},{"key":"key\n\t\t\t\t20171013054448_B6","doi-asserted-by":"crossref","unstructured":"Carthew,P., Edwards,R.E., Nolan,B.M., Martin,E.A., Heydon,R.T., White,I.N.H. and Tucker,M.J. (2000) Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis, 21, 793\u2013797.","DOI":"10.1093\/carcin\/21.4.793"},{"key":"key\n\t\t\t\t20171013054448_B7","doi-asserted-by":"crossref","unstructured":"M\u00e4ntyl\u00e4,E., Nieminen,L. and Karlsson,S. (1995) Endometrial cancer induction by tamoxifen in the rat. Eur. J. Cancer, 31A suppl. 6, S14.","DOI":"10.1016\/0959-8049(95)95313-U"},{"key":"key\n\t\t\t\t20171013054448_B8","doi-asserted-by":"crossref","unstructured":"White,I.N.H. (1999) The tamoxifen dilemma. Carcinogenesis, 20, 1153\u20131160.","DOI":"10.1093\/carcin\/20.7.1153"},{"key":"key\n\t\t\t\t20171013054448_B9","doi-asserted-by":"crossref","unstructured":"Phillips,D.H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839\u2013849.","DOI":"10.1093\/carcin\/22.6.839"},{"key":"key\n\t\t\t\t20171013054448_B10","doi-asserted-by":"crossref","unstructured":"Boocock,D.J., Brown,K., Gibbs,A.H., Sanchez,E., Turteltaub,K.W. and White,I.N. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 23, 1897\u20131901.","DOI":"10.1093\/carcin\/23.11.1897"},{"key":"key\n\t\t\t\t20171013054448_B11","doi-asserted-by":"crossref","unstructured":"Kim,S.Y., Suzuki,N., Santosh Laxmi,Y.R., Rieger,R. and Shibutani,S. (2003) Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol., 16, 1138\u20131144.","DOI":"10.1021\/tx0300131"},{"key":"key\n\t\t\t\t20171013054448_B12","doi-asserted-by":"crossref","unstructured":"Jacolot,F., Simon,I., Dreano,Y., Beaune,P., Riche,C. and Berthou,F. (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41, 1911\u20131919.","DOI":"10.1016\/0006-2952(91)90131-N"},{"key":"key\n\t\t\t\t20171013054448_B13","doi-asserted-by":"crossref","unstructured":"Rajaniemi,H., Rasanen,I., Koivisto,P., Peltonen,K. and Hemminki,K. (1999) Identification of the major tamoxifen\u2013DNA adducts in rat liver by mass spectroscopy. Carcinogenesis, 20, 305\u2013309.","DOI":"10.1093\/carcin\/20.2.305"},{"key":"key\n\t\t\t\t20171013054448_B14","doi-asserted-by":"crossref","unstructured":"Phillips,D.H., Hewer,A., Horton,M.N., Cole,K.J., Carmichael,P.L., Davis,W. and Osborne,M.R. (1999) N-Demethylation accompanies \u03b1-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis, 20, 2003\u20132009.","DOI":"10.1093\/carcin\/20.10.2003"},{"key":"key\n\t\t\t\t20171013054448_B15","doi-asserted-by":"crossref","unstructured":"Brown,K., Heydon,R.T., Jukes,R., White,I.N.H. and Martin,E.A. (1999) Further characterisation of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis, 20, 2011\u20132016.","DOI":"10.1093\/carcin\/20.10.2011"},{"key":"key\n\t\t\t\t20171013054448_B16","doi-asserted-by":"crossref","unstructured":"Gamboa Da Costa,G., Hamilton,L.P., Beland,F.A. and Marques,M.M. (2000) Characterization of the major DNA adduct formed by alpha-hydroxy-N-desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol., 13, 200\u2013207.","DOI":"10.1021\/tx990187b"},{"key":"key\n\t\t\t\t20171013054448_B17","doi-asserted-by":"crossref","unstructured":"Davis,W., Venitt,S. and Phillips,D.H. (1998) The metabolic activation of tamoxifen and \u03b1-hydroxytamoxifen to DNA binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis, 19, 861\u2013866.","DOI":"10.1093\/carcin\/19.5.861"},{"key":"key\n\t\t\t\t20171013054448_B18","unstructured":"Davis,W., Hewer,A., Rajkowski,K.M., Meinl,W., Glatt,H.R. and Phillips,D.H. (2000) Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulphotransferase induction. Cancer Res., 60, 2887\u20132891."},{"key":"key\n\t\t\t\t20171013054448_B19","doi-asserted-by":"crossref","unstructured":"Glatt,H., Davis,W., Meinl,W., Hermersd\u00f6rfer,H., Venitt,S. and Phillips,D.H. (1998) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis, 19, 1709\u20131713.","DOI":"10.1093\/carcin\/19.10.1709"},{"key":"key\n\t\t\t\t20171013054448_B20","unstructured":"Osborne,M.R., Hewer,A., Hardcastle,I.R., Carmichael,P.L. and Phillips,D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66\u201371."},{"key":"key\n\t\t\t\t20171013054448_B21","doi-asserted-by":"crossref","unstructured":"Osborne,M.R., Hardcastle,I.R. and Phillips,D.H. (1997) Minor products of reaction with DNA of \u03b1-acetoxytamoxifen. Carcinogenesis, 18, 539\u2013543.","DOI":"10.1093\/carcin\/18.3.539"},{"key":"key\n\t\t\t\t20171013054448_B22","doi-asserted-by":"crossref","unstructured":"Kitagawa,M., Ravindernath,A., Suzuki,N., Rieger,R., Terashima,I., Umemoto,A. and Shibutani,S. (2000) Identification of tamoxifen\u2013DNA adducts induced by alpha-acetoxy-N-desmethyltamoxifen. Chem. Res. Toxicol., 13, 761\u2013769.","DOI":"10.1021\/tx000074o"},{"key":"key\n\t\t\t\t20171013054448_B23","unstructured":"Han,X. and Liehr,J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360\u20131363."},{"key":"key\n\t\t\t\t20171013054448_B24","doi-asserted-by":"crossref","unstructured":"White,I.N.H., de Matteis,F., Davies,A., Smith,L.L., Crofton-Sleigh,C., Venitt,S., Hewer,A. and Phillips,D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344\/n rats, DBA\/2 and C57Bl\/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197\u20132203.","DOI":"10.1093\/carcin\/13.12.2197"},{"key":"key\n\t\t\t\t20171013054448_B25","doi-asserted-by":"crossref","unstructured":"da Costa,G.G., McDaniel-Hamilton,L.P., Heflich,R.H., Marques,M.M. and Beland,F.A. (2001) DNA adduct formation and mutant induction in Sprague\u2013Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis, 22, 1307\u20131315.","DOI":"10.1093\/carcin\/22.8.1307"},{"key":"key\n\t\t\t\t20171013054448_B26","unstructured":"Li,D., Dragan,Y., Jordan,V.C., Wang,M. and Pitot,H.C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res., 57, 1438\u20131441."},{"key":"key\n\t\t\t\t20171013054448_B27","doi-asserted-by":"crossref","unstructured":"Beland,F.A., McDaniel,L.P. and Marques,M.M. (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis, 20, 471\u2013477.","DOI":"10.1093\/carcin\/20.3.471"},{"key":"key\n\t\t\t\t20171013054448_B28","doi-asserted-by":"crossref","unstructured":"Pathak,D.N., Pongracz,K. and Bodell,W.J. (1996) Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague\u2013Dawley rats treated with tamoxifen. Carcinogenesis, 17, 1785\u20131790.","DOI":"10.1093\/carcin\/17.9.1785"},{"key":"key\n\t\t\t\t20171013054448_B29","doi-asserted-by":"crossref","unstructured":"White,I.N.H., Martin,E.A., Mauthe,R.J., Vogel,J.S., Turtletaub,K.W. and Smith,L.L. (1997) Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem.-Biol. Interact., 106, 149\u2013160.","DOI":"10.1016\/S0009-2797(97)00063-X"},{"key":"key\n\t\t\t\t20171013054448_B30","doi-asserted-by":"crossref","unstructured":"Poirier,M.C. and Schild,L.J. (2003) The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis, 18, 395\u2013399.","DOI":"10.1093\/mutage\/geg005"},{"key":"key\n\t\t\t\t20171013054448_B31","unstructured":"Hemminki,K., Rajaniemi,H., Lindahl,B. and Moberger,B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374\u20134377."},{"key":"key\n\t\t\t\t20171013054448_B32","doi-asserted-by":"crossref","unstructured":"Shibutani,S., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (1999) Tamoxifen\u2013DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 12, 646\u2013653.","DOI":"10.1021\/tx990033w"},{"key":"key\n\t\t\t\t20171013054448_B33","doi-asserted-by":"crossref","unstructured":"Shibutani,S., Ravindernath,A., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (2000) Identification of tamoxifen\u2013DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 21, 1461\u20131467.","DOI":"10.1093\/carcin\/21.8.1461"},{"key":"key\n\t\t\t\t20171013054448_B34","unstructured":"Martin,E.A., Brown,K., Gaskell,M., Al-Azzawi,F., Garner,R.C., Boocock,D.J., Mattock,E., Pring,D.W., Dingley,K., Turteltaub,K.W., Smith,L.L. and White,I.N. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res., 63, 8461\u20138465."},{"key":"key\n\t\t\t\t20171013054448_B35","unstructured":"Orton,T.C. and Topham,J.C. (1997) Correspondence re: K. Hemminki et al., Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56: 4374\u20134377, 1996. Cancer Res., 57, 4148."},{"key":"key\n\t\t\t\t20171013054448_B36","unstructured":"Carmichael,P.L., Ugwumadu,A.H.N., Neven,P., Hewer,A., Poon,G.K. and Phillips,D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475\u20131479."},{"key":"key\n\t\t\t\t20171013054448_B37","doi-asserted-by":"crossref","unstructured":"Carmichael,P.L., Sardar,S., Crooks,N., Neven,P., Van Hoof,I., Ugwumadu,A., Bourne,T., Tomas,E., Hellberg,P., Hewer,A.J. and Phillips,D.H. (1999) Lack of evidence from HPLC 32P-post-labelling for tamoxifen\u2013DNA adducts in the human endometrium. Carcinogenesis, 20, 339\u2013342.","DOI":"10.1093\/carcin\/20.2.339"},{"key":"key\n\t\t\t\t20171013054448_B38","doi-asserted-by":"crossref","unstructured":"Beland,F.A., Churchwell,M.I., Doerge,D.R., Parkin,D.R., Malejka-Giganti,D., Hewer,A., Phillips,D.H., Carmichael,P.L., Gamboa da Costa,G. and Marques,M.M. (2004) Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen\u2013DNA adducts in humans. J. Natl Cancer Inst., 96, 1099\u20131104.","DOI":"10.1093\/jnci\/djh195"},{"key":"key\n\t\t\t\t20171013054448_B39","doi-asserted-by":"crossref","unstructured":"Beland,F.A., Churchwell,M.I., Hewer,A., Phillips,D.H., da Costa,G.G. and Marques,M.M. (2004) Analysis of tamoxifen\u2013DNA adducts in endometrial explants by MS and 32P-postlabeling. Biochem. Biophys. Res. Commun., 320, 297\u2013302.","DOI":"10.1016\/j.bbrc.2004.05.168"},{"key":"key\n\t\t\t\t20171013054448_B40","doi-asserted-by":"crossref","unstructured":"Sharma,M., Shubert,D.E., Rodabaugh,K.J., McGarrigle,B.P., Vezina,C.M., Bofinger,D.P. and Olson,J.R. (2003) Antioxidant inhibits tamoxifen\u2013DNA adducts in endometrial explant culture. Biochem. Biophys. Res. Commun., 307, 157\u2013164.","DOI":"10.1016\/S0006-291X(03)01134-3"},{"key":"key\n\t\t\t\t20171013054448_B41","doi-asserted-by":"crossref","unstructured":"Brown,K. and Carmichael,P.L. (2003) Correspondence regarding M. Sharma et al., \u2018Antioxidant inhibits tamoxifen\u2013DNA adducts in endometrial explant culture\u2019. Biochem. Biophys. Res. Commun., 310, 1039.","DOI":"10.1016\/j.bbrc.2003.09.101"},{"key":"key\n\t\t\t\t20171013054448_B42","doi-asserted-by":"crossref","unstructured":"Sharma,M. (2004) Correspondence regarding October 31, 2003, Breakthroughs and Views by K. Brown and P.L. Carmichael. Biochem. Biophys. Res. Commun., 313, 1\u20132.","DOI":"10.1016\/j.bbrc.2003.11.106"},{"key":"key\n\t\t\t\t20171013054448_B43","doi-asserted-by":"crossref","unstructured":"Foster,A.B., Jarman,M., Leung,O.-T., McCague,R., Leclercq,G. and Devleeschouwer,N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem., 28, 1491\u20131497.","DOI":"10.1021\/jm00148a020"},{"key":"key\n\t\t\t\t20171013054448_B44","doi-asserted-by":"crossref","unstructured":"Phillips,D.H., Carmichael,P.L., Hewer,A., Cole,K.J., Hardcastle,I.R., Poon,G.K., Keogh,A. and Strain,A.J. (1996) Activation of tamoxifen and its metabolite \u03b1-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 88\u201394.","DOI":"10.1093\/carcin\/17.1.89"},{"key":"key\n\t\t\t\t20171013054448_B45","doi-asserted-by":"crossref","unstructured":"Reddy,M.V. and Randerath,K. (1986) Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis, 7, 1543\u20131551.","DOI":"10.1093\/carcin\/7.9.1543"},{"key":"key\n\t\t\t\t20171013054448_B46","doi-asserted-by":"crossref","unstructured":"Phillips,D.H., Hewer,A., Grover,P.L., Poon,G.K. and Carmichael,P.L. (1996) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149\u20131152.","DOI":"10.1093\/carcin\/17.5.1149"},{"key":"key\n\t\t\t\t20171013054448_B47","unstructured":"Venitt,S., Crofton-Sleigh,C. and Forster,R. (1984) Bacterial mutation assays using reverse mutation. In Venitt,S. and Parry,J.M. (eds), Mutagenicity Testing: a Practical Approach. IRL Press, Oxford, Washington DC, pp. 45\u201398."},{"key":"key\n\t\t\t\t20171013054448_B48","unstructured":"Grant,D.M., Josephy,P.D., Lord,H.L. and Morrison,L.D. (1992) Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res., 52, 3961\u20133964."},{"key":"key\n\t\t\t\t20171013054448_B49","doi-asserted-by":"crossref","unstructured":"Arlt,V.M., Glatt,H., Muckel,E., Pabel,U., Sorg,B.L., Schmeiser,H.H. and Phillips,D.H. (2002) Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis, 23, 1937\u20131945.","DOI":"10.1093\/carcin\/23.11.1937"},{"key":"key\n\t\t\t\t20171013054448_B50","doi-asserted-by":"crossref","unstructured":"Newbold,R.R., Jefferson,W.N., Padilla-Burgos,E. and Bullock,B.C. (1997) Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis, 18, 2293\u20132298.","DOI":"10.1093\/carcin\/18.12.2293"},{"key":"key\n\t\t\t\t20171013054448_B51","doi-asserted-by":"crossref","unstructured":"da Costa,G.G., Manjanatha,M.G., Marques,M.M. and Beland,F.A. (2002) Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen. Cancer Lett., 176, 37\u201345.","DOI":"10.1016\/S0304-3835(01)00741-8"},{"key":"key\n\t\t\t\t20171013054448_B52","doi-asserted-by":"crossref","unstructured":"Brown,K., Brown,J.E., Martin,E.A., Smith,L.L. and White,I.N.H. (1998) Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues. Chem. Res. Toxicol., 11, 527\u2013534.","DOI":"10.1021\/tx9702289"},{"key":"key\n\t\t\t\t20171013054448_B53","unstructured":"Phillips,D.H., Carmichael,P.L., Hewer,A., Cole,K.J. and Poon,G.K. (1994) \u03b1-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518\u20135522."},{"key":"key\n\t\t\t\t20171013054448_B54","doi-asserted-by":"crossref","unstructured":"Boocock,D.J., Maggs,J.L., Brown,K., White,I.N.H. and Park,B.K. (2000) Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of \u03b1-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen\u2013DNA adducts. Carcinogenesis, 21, 1851\u20131858.","DOI":"10.1093\/carcin\/21.10.1851"},{"key":"key\n\t\t\t\t20171013054448_B55","doi-asserted-by":"crossref","unstructured":"Phillips,D.H., Farmer,P.B., Beland,F.A., Nath,R.G., Poirier,M.C., Reddy,M.V. and Turteltaub,K.W. (2000) Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ. Mol. Mutagen., 35, 222\u2013233.","DOI":"10.1002\/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E"},{"key":"key\n\t\t\t\t20171013054448_B56","doi-asserted-by":"crossref","unstructured":"Phillips,D.H., Hewer,A. and Osborne,M.R. (1992) Interaction of omeprazole with DNA in rat tissues. Mutagenesis, 7, 277\u2013283.","DOI":"10.1093\/mutage\/7.4.277"},{"key":"key\n\t\t\t\t20171013054448_B57","doi-asserted-by":"crossref","unstructured":"Carthew,P., Edwards,R.E., Nolan,B.M., Martin,E.A. and Smith,L.L. (1996) Tamoxifen associated uterine pathology in rodents: relevance to women. Carcinogenesis, 17, 1577\u20131582.","DOI":"10.1093\/carcin\/17.8.1577"},{"key":"key\n\t\t\t\t20171013054448_B58","doi-asserted-by":"crossref","unstructured":"Schild,L.J., Phillips,D.H., Osborne,M.R., Hewer,A., Beland,F.A., Churchwell,M.I., Brown,K., Gaskell,M., Wright,E. and Poirier,M.C. (2005) Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods. Mutagenesis, 20, 115\u2013124.","DOI":"10.1093\/mutage\/gei015"},{"key":"key\n\t\t\t\t20171013054448_B59","unstructured":"Schild,L.J., Divi,R.L., Beland,F.A., Churchwell,M.I., Doerge,D.R., Gamboa da Costa,G., Marques,M.M. and Poirier,M.C. (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res., 63, 5999\u20136003."},{"key":"key\n\t\t\t\t20171013054448_B60","unstructured":"Shibutani,S., Suzuki,N., Laxmi,Y.R., Schild,L.J., Divi,R.L., Grollman,A.P. and Poirier,M.C. (2003) Identification of tamoxifen\u2013DNA adducts in monkeys treated with tamoxifen. Cancer Res., 63, 4402\u20134406."},{"key":"key\n\t\t\t\t20171013054448_B61","unstructured":"Shibutani,S., Dasaradhi,L., Terashima,I., Banoglu,E. and Duffel,M.W. (1998) Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen\u2013DNA adducts. Cancer Res., 58, 647\u2013653."},{"key":"key\n\t\t\t\t20171013054448_B62","doi-asserted-by":"crossref","unstructured":"Apak,T.I. and Duffel,M.W. (2004) Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab. Dispos., 32, 1501\u20131508.","DOI":"10.1124\/dmd.104.000919"},{"key":"key\n\t\t\t\t20171013054448_B63","doi-asserted-by":"crossref","unstructured":"Rubin,G.L., Harrold,A.J., Mills,J.A., Falany,C.N. and Coughtrie,M.W. (1999) Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. Mol. Hum. Reprod., 5, 995\u20131002.","DOI":"10.1093\/molehr\/5.11.995"},{"key":"key\n\t\t\t\t20171013054448_B64","doi-asserted-by":"crossref","unstructured":"Wallen,M., Tomas,E., Visakorpi,T., Holli,K. and Maenpaa,J. (2005) Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother. Pharmacol., 55, 343\u2013346.","DOI":"10.1007\/s00280-004-0923-x"},{"key":"key\n\t\t\t\t20171013054448_B65","doi-asserted-by":"crossref","unstructured":"Karlsson,S., Hirsimaki,Y., Mantyla,E., Nieminen,L., Kangas,L., Hirsimaki,P., Perry,C.J., Mulhern,M., Millar,P., Handa,J. and Williams,G.M. (1996) A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague\u2013Dawley rats. Drug Chem. Toxicol., 19, 245\u2013266.","DOI":"10.3109\/01480549608998236"},{"key":"key\n\t\t\t\t20171013054448_B66","doi-asserted-by":"crossref","unstructured":"Rajaniemi,H., Mantyla,E. and Hemminki,K. (1998) DNA adduct formation by tamoxifen and structurally-related compounds in rat liver. Chem. Biol. Interact., 113, 145\u2013159.","DOI":"10.1016\/S0009-2797(98)00023-4"},{"key":"key\n\t\t\t\t20171013054448_B67","doi-asserted-by":"crossref","unstructured":"Prasad,M., Wang,H., Douglas,W., Barakat,R.R. and Ellenson,L.H. (2005) Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol. Oncol., 96, 25\u201331.","DOI":"10.1016\/j.ygyno.2004.08.046"}],"container-title":["Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mutage\/article-pdf\/20\/4\/297\/3689959\/gei038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T05:47:37Z","timestamp":1507873657000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/mutage\/article\/20\/4\/297\/1069235\/Organ-specificity-of-DNA-adduct-formation-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,31]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,5,31]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mutage\/gei038","relation":{},"ISSN":["1464-3804","0267-8357"],"issn-type":[{"value":"1464-3804","type":"electronic"},{"value":"0267-8357","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7]]},"published":{"date-parts":[[2005,5,31]]}}}